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Dear Sir,
The interesting article by Fabris et al. shows that individu-
als screened for antiphospholipid antibodies (aPL) because 
of a thrombotic or obstetric history exhibit higher platelet-
activating factor acetylhydrolase (PAF-AH) in plasma than 
control blood donors (p < 0.0001); amongst the aPL-pos-
itive participants, those lupus anticoagulant positive had 
higher PAF-AH than LA-negative patients (p = 0.03) and 
those positive for IgG anti-beta2 glycoprotein-I antibodies 
(aβ2GPI) presented with higher PAF-AH than patients posi-
tive for isolated IgM aβ2GPI (p = 0.03) [1].
To expand on this topic, we measured PAF-AH in 27 
consecutive thrombotic primary antiphospholipid syndrome 
(PAPS) patients, in 17 thrombotic patients with inherited 
thrombophilia (IT) and in 23 healthy controls had given 
written consent for their plasma samples to be stored for 
research purposes (Table 1). In all participants, we meas-
ured IgG anticardiolipin (Cambridge Life Sciences, UK), 
IgG aβ2GPI (Corgenix, Denver, USA), β2GPI-oxidised 
low-density lipoprotein (β2GPI-oxLDL) complex and IgG 
anti-β2GPI-oxLDL by previously described immunoassays 
[2, 3], and PAF-AH by an established method [4]. Lipid 
profiles were normal in all participants according to meas-
urements done two to three months earlier than the present 
measurements.
Table 1 shows the results: IgG aPL were elevated by defi-
nition in the PAPS group but median PAF-AH was lower 
in PAPS compared to the other groups (p = 0.03); PAF-
AH correlated (Spearman rank) positively to β2GPI-oxLDL 
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Table 1  Demographics and clinical features of the study populations
All numerical data expressed as median and range. p  =  0.03 by 
Kruskal–Wallis ANOVA
CTR controls, IT inherited thrombophilia, PAPS primary antiphos-
pholipid syndrome, FVL factor V Leiden, PT prothrombin 20210, PC 
protein C, IS ischaemic stroke, MI myocardial infarction, DVT deep 
vein thrombosis, PE pulmonary embolism
a p = 0.03
CTR IT PAPS
Participants (no.) 23 17 27
Female/male 13/7 11/6 18/9
Age (range) 42 (19–55) 40 (30–58) 38 (27–53)
Lupus anticoagulant 0 0 28
IgGaCL (GPL) 3 (1.5–6.0) 3.2 (1.4–6.8) 122 (24–573)
IgGβ2GPI (IU) 1 (0.78–3.4) 2 (0.8–4.8) 183 (31–226)
β2GPI-oxLDL (IU) 1.6 (1.0–9.0) 1.6 (0.5–6.5) 1.4 (0.8–1.8)
PAF-AH (nmol/ml/min) 46 (22–88) 43 (30–79) 39 (1.8–80)a
FVL 0 12 2
PT 20210 1 2 1
PC deficiency 0 3 0
IS 0 2 7
MI 0 0 1
DVT 0 11 14
PE 0 4 5
Smoking 2 2 4
Diabetes 0 0 0
Obesity 0 0 0
Aspirin (75 mg) 0 3 1
Warfarin 0 14 26
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in the CTR (r = 0.49, p = 0.01) and in the IT (r = 0.56, 
p  =  0.02) groups but negatively in the PAPS group 
(r = − 0.4, p = 0.03). In the latter group, free radical over-
generation [5] may inhibit PAF-AH activity [6] perpetuating 
the effect of PAF that adds to the agonists favouring plate-
let activation alongside isoprostane [5], thromboxane [7] 
and thrombin [8]. Our data on low PAF-AH in established 
PAPS contrast with those of Fabris et al. [1] who do not 
provide the aPL titres of their screened population and fail 
to divide participants according to the vascular or obstetric 
manifestations of APS limiting the interpretation of their 
data. Our PAPS patients with arterial thrombosis showed a 
slightly lower PAF-AH than patients with venous thrombo-
sis (33 ± 36 vs 38 ± 61 nmol/ml/min, non significant). In 
keeping with Fabris [1], we agree that larger studies with 
clearly defined subsets of patients are required to have a 
clearer picture on the thrombotic and/or atherogenic role of 
PAF-AH [9] in PAPS.
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